<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="107630">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01951963</url>
  </required_header>
  <id_info>
    <org_study_id>A12-158</org_study_id>
    <nct_id>NCT01951963</nct_id>
  </id_info>
  <brief_title>Sub-dissociative Ketamine for the Management of Acute Pediatric Pain</brief_title>
  <official_title>Sub-dissociative Ketamine for the Management of Acute Pediatric Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>HealthPartners Institute for Education and Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>HealthPartners Institute for Education and Research</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The proposed trial is a prospective, double blinded, randomized control trial with the
      primary aim of determining whether a single, sub-dissociative dose of ketamine will decrease
      the total narcotic requirements of pediatric patients requiring intravenous analgesia in an
      urban emergency department (ED) compared to a group of patients who receive morphine alone
      for pain management. Patients are randomized to receive either a single bolus of ketamine
      (0.3 mg/kg) or a single bolus of morphine (0.05mg/kg). All subsequent pain management will
      be accomplished using morphine. Patient, family member, and research staff pain scores will
      be recorded, until 3 hours post study medication administration.  Family members are
      contacted via telephone 24 hours post-ED discharge, and again at 7 days post-hospital
      discharge, for evaluation via Post Hospitalization Behavior Questionnaire. Narcotic
      equivalents will be calculated for up to 3 hours post study medication administration and
      compared between the ketamine and morphine groups.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Cumulative narcotic consumption</measure>
    <time_frame>3 hours post study drug administration</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse drug reaction</measure>
    <time_frame>3 hours post study drug administration</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in self-assessed pain rating</measure>
    <time_frame>3 hours post study medication administration</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Pain scale rating agreement among patient, parent, and research staff</measure>
    <time_frame>15 minute increments for 3 hours post pain medication administration</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Pain</condition>
  <condition>Pediatrics</condition>
  <arm_group>
    <arm_group_label>Ketamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ketamine, single dose, 0.3 mg/kg, IV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Morphine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Morphine, single dose, 0.05 mg/kg, IV</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine</intervention_name>
    <arm_group_label>Ketamine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Morphine</intervention_name>
    <arm_group_label>Morphine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age: 3-17 years old

          -  Condition (medical or trauma) requiring opioid pain management per standard of care

          -  Need to establish an IV per standard of care

          -  Treating physician agrees to manage the patient's pain with morphine following
             randomization.

        Exclusion Criteria:

          -  Trauma Team Activation

          -  Known allergy to ketamine

          -  Family member unable/unavailable to provide informed consent

          -  When appropriate, patient unwilling to provide assent

          -  High suspicion of injury related to child abuse

          -  Patient and/or family member is non-English speaking

          -  Patient is incarcerated
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aaron M Burnett, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Regions Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sandi S Wewerka, MPH</last_name>
    <phone>651-254-5304</phone>
    <email>sandi.s.wewerka@healthpartners.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Regions Hospital</name>
      <address>
        <city>St. Paul</city>
        <state>Minnesota</state>
        <zip>55101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandi S Wewerka, MPH</last_name>
      <phone>651-254-5304</phone>
      <email>sandi.s.wewerka@healthpartners.com</email>
    </contact>
    <investigator>
      <last_name>Aaron M Burnett, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>September 24, 2013</lastchanged_date>
  <firstreceived_date>September 24, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pain management</keyword>
  <keyword>ketamine</keyword>
  <keyword>morphine</keyword>
  <keyword>pediatrics</keyword>
  <keyword>emergency medicine</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ketamine</mesh_term>
    <mesh_term>Morphine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
